A four-group urine risk classifier for predicting outcomes in patients with prostate cancer

Autor: Connell, Shea P., Yazbek-Hanna, Marcelino, McCarthy, Frank, Hurst, Rachel, Webb, Martyn, Curley, Helen, Walker, Helen, Mills, Rob, Ball, Richard Y., Sanda, Martin G., Pellegrini, Kathryn L., Patil, Dattatraya, Perry, Antoinette S., Schalken, Jack, Pandha, Hardev, Whitaker, Hayley, Dennis, Nening, Stuttle, Christine, Mills, Ian G., Guldvik, Ingrid, Parker, Chris, Brewer, Daniel S., Cooper, Colin S., Clark, Jeremy, Bapat, Bharati, Bristow, Rob, Doll, Andreas, Cooper, Colin, Leung, Hing, Mills, Ian, Neal, David, Olivan, Mireia, Perry, Antoinette, Sanda, Martin
Rok vydání: 2019
Předmět:
Zdroj: Bju International
BJU International, 124, 4, pp. 609-620
BJU International, 124, 609-620
ISSN: 1464-4096
Popis: Objectives To develop a risk classifier using urine‐derived extracellular vesicle (EV)‐RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS). Patients and Methods Post‐digital rectal examination urine‐derived EV‐RNA expression profiles (n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO‐based continuation ratio model was built to generate four prostate urine risk (PUR) signatures for predicting the probability of normal tissue (PUR‐1), D'Amico low‐risk (PUR‐2), intermediate‐risk (PUR‐3), and high‐risk (PUR‐4) prostate cancer. This model was applied to a test cohort (n = 177) for diagnostic evaluation, and to an AS sub‐cohort (n = 87) for prognostic evaluation. Results Each PUR signature was significantly associated with its corresponding clinical category (P < 0.001). PUR‐4 status predicted the presence of clinically significant intermediate‐ or high‐risk disease (area under the curve = 0.77, 95% confidence interval [CI] 0.70–0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub‐cohort (n = 87), groups defined by PUR status and proportion of PUR‐4 had a significant association with time to progression (interquartile range hazard ratio [HR] 2.86, 95% CI 1.83–4.47; P < 0.001). PUR‐4, when used continuously, dichotomized patient groups with differential progression rates of 10% and 60% 5 years after urine collection (HR 8.23, 95% CI 3.26–20.81; P < 0.001). Conclusion Urine‐derived EV‐RNA can provide diagnostic information on aggressive prostate cancer prior to biopsy, and prognostic information for men on AS. PUR represents a new and versatile biomarker that could result in substantial alterations to current treatment of patients with prostate cancer.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje